Vor Biopharma Inc. (VOR) stock
Close on Nov 11, 2026Market cap $1.23BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.23B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -9.70%
Fundamentals
- Net income
- $1.35B
- EPS, diluted
- -$70.50
- Free cash flow
- -$119.68M
- Book value per share
- -$2.30
- Diluted shares
- 60M
Trading
- Previous close
- $19.56
- Open
- $19.73
- Day's range
- $19.57 – $20.30
- Volume
- 407,786
- Average volume (20 days)
- 712,223
- Index membership
- Russell 2000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 2.09
- 52-week range
- $6.50 – $26.00
- RSI (14 days)
- 52.8
- Volatility (1 year)
- 105.0%
- Relative volume
- 0.43×
- WACC
- 15.4%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | VOR | S&P 500 | Difference | VOR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.0% | -2.4% | +3.4 pts | ||
| 3 months | -14.8% | -1.2% | −13.7 pts | ||
| Year to date | +53.6% | +12.3% | +41.3 pts | ||
| 1 year | +104.2% | +12.4% | +91.7 pts | ||
| 3 years | -42.9% | +78.8% | −121.7 pts | -17.1% | +21.4% |
| 5 years | -94.0% | +75.2% | −169.2 pts | -43.0% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vor Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Results
- Update
About Vor Biopharma
Biological Products, (No Diagnostic Substances)
Vor Biopharma Inc. is a clinical-stage biopharmaceutical company that develops therapies for autoimmune diseases. Its primary product candidate is telitacicept, a novel fusion protein designed to inhibit B cell lymphocyte stimulator and a proliferation-inducing ligand. By targeting these signaling molecules, the therapy reduces autoimmune responses driven by B cells. The company develops treatments for chronic conditions such as generalized myasthenia gravis and Sjögren’s disease, aiming to serve patients suffering from these neuromuscular and autoimmune illnesses.
Company profile, executives and historyVor Biopharma stock: common questions
What is Vor Biopharma's stock price?
VOR closed at $20.09 on Nov 11, 2026, up 2.71% on the day. Over the past 52 weeks it traded between $6.50 and $26.00.
What is Vor Biopharma's market cap?
Vor Biopharma was worth $1.23B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is VOR's P/E ratio?
Vor Biopharma lost money over fiscal 2025 (diluted EPS -$70.50), so it has no meaningful P/E ratio.
Does Vor Biopharma pay a dividend?
No. Vor Biopharma has not paid a cash dividend over the last twelve months.
How has VOR stock performed over the past year?
Including dividends, VOR returned +104.2% over the past year, against +12.4% for the S&P 500.
Who are Vor Biopharma's competitors?
Companies most similar to Vor Biopharma by business, industry and size include CABA, CGEM, IMA, ZURA, INMB.
See a number that looks wrong?